Table 1. Summary of demographic characteristics.
| Parameters | Overall | Amlodipine (n=2460) | Amlodipine+ telmisartan (n=2847) | Amlodipine+ atenolol (n=477) | Amlodipine+ bisoprolol (n=639) | Amlodipine+ metoprolol (n=1356) | Amlodipine+ chlorthalidone+ telmisartan (n=429) | Amlodipine+ hydrochlorothiazide+ telmisartan (n=1557) | Amlodipine+ hydrochlorothiazide+ olmesartan (n=429) | |
| Age, N (mean ±SD) | 18-39 | 1,088 (33.91±4.45) | 182 (32.9±4.9) | 264 (34.5±4.2) | 44 (34.6±3.9) | 91 (34.4±3.8) | 174 (33.5±4.6) | 28 (34.7±3.1) | 145 (34.6±3.8) | 36 (34.2±5.0) |
| 40-64 | 6,675 (52.96±6.86) | 1513 (52.9±6.9) | 1882 (53.0±6.8) | 316 (53.2±6.8) | 415 (52.8±6.8) | 894 (52.8±7.0) | 298 (52.9±6.9) | 1079 (53.1±6.9) | 278 (53.4±6.5) | |
| ≥ 65 | 2,431 (70.51±5.21) | 641 (70.9±5.5) | 701 (70.4±5.1) | 117 (70.6±5.7) | 133 (70.8±5.4) | 288 (70.6±4.8) | 103 (71.6±5.7) | 333 (69.8±4.7) | 115 (69.8±5.3) | |
| Gender, n (%) | Male | 5,388 (52.85) | 1334 (54.2) | 1505 (52.9) | 241 (50.5) | 345 (54.0) | 692 (51.0) | 233 (54.3) | 816 (52.4) | 222 (51.7) |
| Comorbities, n (%) | Dyslipidemia | - | 878 (35.69%) | 1051 (36.92%) | 160 (33.54%) | 285 (44.60%) | 550 (40.56%) | 166 (38.69%) | 572 (36.74%) | 179 (41.72%) |
| DM | - | 816 (33.17%) | 1306 (45.87%) | 199 (41.72%) | 222 (34.74%) | 472 (34.81%) | 183 (42.66%) | 691 (44.38%) | 197 (45.92%) | |
| CKD | - | 243 (9.88%) | 65 (2.28%) | 27 (5.66%) | 34 (5.32%) | 98 (7.23%) | 8 (1.86%) | 14 (0.90%) | 7 (1.63%) | |
| CAD | - | 185 (7.52%) | 165 (5.80%) | 39 (8.18%) | 68 (10.64%) | 104 (7.67%) | 25 (5.83%) | 87 (5.59%) | 30 (6.99%) | |
| Dyslipidemia+DM | - | 419 (17.03%) | 601 (21.11%) | 87 (18.24%) | 132 (20.66%) | 265 (19.54%) | 81 (18.88%) | 320 (20.55%) | 103 (24.01%) | |
| Dyslipidemia+CKD | - | 85 (3.46%) | 33 (1.16%) | 15 (3.14%) | 23 (3.60%) | 45 (3.32%) | 3 (0.70%) | 10 (0.64%) | 4 (0.93%) | |
| Dyslipidemia+CAD | - | 150 (6.10%) | 120 (4.21%) | 30 (6.29%) | 54 (8.45%) | 88 (6.49%) | 18 (4.20%) | 69 (4.43%) | 22 (5.13%) | |
| DM+CKD | - | 72 (2.93%) | 30 (1.05%) | 9 (1.89%) | 17 (2.66%) | 44 (3.24%) | 7 (1.63%) | 12 (0.77%) | 3 (0.70%) | |
| DM+CAD | - | 79 (3.21%) | 75 (2.63%) | 18 (3.77%) | 24 (3.76%) | 47 (3.47%) | 9 (2.10%) | 33 (2.12%) | 13 (3.03%) | |
| CAD+CKD | - | 22 (0.89%) | 7 (0.25%) | 2 (0.42%) | 7 (1.10%) | 10 (0.74%) | 1 (0.23%) | 3 (0.19%) | 1 (0.23%) | |
| Dyslipidemia+DM+CKD | - | 38 (1.54%) | 18 (0.63%) | 8 (1.68%) | 13 (2.03%) | 27 (1.99%) | 3 (0.70%) | 8 (0.51%) | 2 (0.47%) | |
| Dyslipidemia+DM+CAD | - | 66 (2.68%) | 57 (2.00%) | 16 (3.35%) | 21 (3.29%) | 43 (3.17%) | 7 (1.63%) | 29 (1.86%) | 11 (2.56%) | |
| Dyslipidemia+CAD+CKD | 17 (0.69%) | 5 (0.18%) | 2 (0.42%) | 5 (0.78%) | 8 (0.59%) | 2 (0.13%) | 1 (0.23%) | |||
| DM+CAD+CKD | 9 (0.37%) | 5 (0.18%) | 1 (0.21%) | 3 (0.47%) | 7 (0.52%) | 1 (0.23%) | 3 (0.19%) | |||
| Dyslipidemia + DM + CAD + CKD | 8 (0.33%) | 3 (0.11%) | 1 (0.21%) | 3 (0.47%) | 6 (0.44%) | 2 (0.13%) | ||||